BioTech
-
Cerevel drug for Parkinson’s improved symptom control in trial
Cerevel Therapeutics, a neuroscience biotech that AbbVie is acquiring, reported that its drug for Parkinson’s disease improved motor symptom control…
Read More » -
Eli Lilly, Amylyx, Johnson & Johnson
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your…
Read More » -
Zepbound effective in obstructive sleep apnea trials
Eli Lilly reported positive results of its obesity drug Zepbound in obstructive sleep apnea, giving the medication a new edge…
Read More » -
Readout newsletter: Biohaven, insulin, biosimilars
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your…
Read More » -
Intra-Cellular reports positive results in depression study
Intra-Cellular Therapies reported positive results Tuesday from a late-stage clinical trial seeking to expand the use of its antipsychotic medicine…
Read More » -
Readout newsletter: Vir, Pfizer, Seagan
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your…
Read More » -
Ultragenyx reports early success with Angelman syndrome drug
Ultragenyx has found early success with its experimental treatment for the rare disease Angelman syndrome, supporting the company’s decision to…
Read More » -
U.S. Scrutiny of Chinese Company Could Disrupt U.S. Supply Chain for Key Drugs
A Chinese company targeted by members of Congress over potential ties to the Chinese government makes blockbuster drugs for the…
Read More » -
Can investing in infectious disease pay off? Vir shows its a struggle
Nearly a decade ago, venture capitalist Bob Nelsen called industry veteran Vicki Sato to pitch her on launching a large…
Read More » -
Readout Newsletter: Moderna, Vertex, Otsuka, Vera
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your…
Read More »